#AsukaPharmaceuticalHoldings

Asuka Pharmaceutical Holdings has formulated the long-term vision "ASKA VISION 2035" looking ahead to 2035 and the "Medium-Term Management Plan 2028" for the three years starting fiscal 2026, targeting net sales of 85 billion yen and an operating income margin of 10%.

Asuka Pharmaceutical Holdings decided to introduce a restricted stock incentive plan through the Employee Shareholding Association on March 2, 2026.

Asuka Pharmaceutical Holdings Co., Ltd. has resolved to transition to a company with an audit and supervisory committee, subject to approval at the 5th Annual General Meeting of Shareholders scheduled for June 24, 2026.

For the third quarter of the fiscal year ending March 2026, net sales amounted to ¥54,486 million (9.1% Year-over-Year increase), operating income was ¥4,911 million (10.6% Year-over-Year decrease), and net income attributable to owners of the parent was ¥3,904 million (4.7% Year-over-Year decrease).

Net sales of 54.4 billion yen, a 9.1% increase year-over-year. Operating income was 4.9 billion yen, a 10.6% decrease year-over-year. Full-year earnings guidance forecasts net sales of 71.0 billion yen and operating income of 6.0 billion yen.